tiprankstipranks
Advertisement
Advertisement
Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity
PremiumRatingsBuy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity
2M ago
Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright
Premium
The Fly
Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright
2M ago
Buy Rating on Structure Therapeutics: Aleniglipron’s Strengthening Clinical Profile and Undervalued Global Obesity Opportunity
Premium
Ratings
Buy Rating on Structure Therapeutics: Aleniglipron’s Strengthening Clinical Profile and Undervalued Global Obesity Opportunity
2M ago
Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright
PremiumThe FlyStructure Therapeutics price target raised to $114 from $90 at H.C. Wainwright
2M ago
Structure Therapeutics price target lowered to $113 from $120 at Citizens
Premium
The Fly
Structure Therapeutics price target lowered to $113 from $120 at Citizens
2M ago
Buy Rating on Structure Therapeutics: Strong Phase II Data and Upcoming Late‑Stage Catalysts Support Upside for Oral GLP‑1 Aleniglipron
Premium
Ratings
Buy Rating on Structure Therapeutics: Strong Phase II Data and Upcoming Late‑Stage Catalysts Support Upside for Oral GLP‑1 Aleniglipron
2M ago
Structure Therapeutics moved to Buy rating at Goldman Sachs
PremiumThe FlyStructure Therapeutics moved to Buy rating at Goldman Sachs
3M ago
Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
Premium
The Fly
Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
4M ago
Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports
Premium
The Fly
Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100